Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 27, 2015 12:46 AM ET


Company Overview of PhaseRx, Inc.

Company Overview

PhaseRx, Inc. is developing RNA nanomedicines for the treatment of orphan liver disease. Its SMARTT Polymer Technology provides the ability to deliver messenger RNA therapeutics to selected tissues in vivo, thereby unlocking the value of mRNA as a therapeutic modality. The company was incorporated in 2006 and is based in Seattle, Washington.

410 West Harrison Street

Suite 300

Seattle, WA 98119

United States

Founded in 2006





Key Executives for PhaseRx, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 57
Co-Founder, Chief Scientific Officer and Director
Age: 71
Compensation as of Fiscal Year 2014.

PhaseRx, Inc. Key Developments

PhaseRx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM

PhaseRx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Robert W. Overell, Co-Founder, Chief Executive Officer, President and Director.

PhaseRx, Inc. Appoints Michael Houston as Vice President, Therapeutics Development

PhaseRx, Inc. announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development. Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx. He has directed numerous programs ranging from research to GMP manufacture of clinical trials materials, including nanoparticle-based delivery vehicles for siRNAs. In this new position, Dr. Houston will lead PhaseRx's therapeutics program, which focuses on the advancement of its SMARTT Polymer Technology(R) mRNA nanoparticles. Dr. Houston joins PhaseRx from Marina Biotech where he served as Vice President, Chemistry and Formulations and focused on the development of siRNAS and single stranded oligonucleotides. He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations.

Similar Private Companies By Industry

Company Name Region
KCM Biomedical United States
Avecia Biotechnology, Inc. United States
Empire Genomics, LLC United States
Cahaba Pharmaceuticals, LLC United States
Human Longevity, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PhaseRx, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at